Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the trial miss was a significant setback that could curb demand for CagriSema, temper long-term sales hopes and leave Novo struggling to win back share in the fast-growing obesity treatment market."
— J.P. Morgan analysts , Executive
"Sigo siendo muy optimista con respecto a CagriSema."
— Mike Doustdar , Executive
Key People
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaTdmamc4QU9IekYyT2hOdlVOdlowVjFnZE84b29mN3RuNXFUMURRaUEwTUkzMEwxVllJT3NzdHo3ZjNoYmJmZk41QUpkSTRacmdCd2ZpSVkxdE1icFVXUVVOVUExblRobUpuT2FUSV8td3dCUS00dm5NYU5LYmFTTEdLT0lhQm9naEczT2lySU9GSS1ZUFpEZnNCemFVUk9lejMxR2RBVFNScFBRamlpbEpjQU1iX0RmVjlJVXZJR0k2T2dGZkJWVWItaDY4czE3YkdTT1Fab05tUQ?oc=5" target="_blank">Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out</a> <font color="#6f6f6f">Reuters</font>
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy’s launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly’s tirzepatide in a trial.
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk ha sufrido una nueva caída en Bolsa tras anunciar que los ensayos clínicos de su nuevo medicamento contra la obesidad, CagriSema, no alcanzaron el criterio principal de efectividad frente a su competidor Tirzepatida, comercializado por Eli Lilly.
Similar Stories
Related coverage based on topic and tags
Dental firm vVardis reveals revenue surge in US IPO filing - Reuters
Dental firm vVardis reveals revenue surge in US IPO filing Reuters
October 9, 2026 at 07:31 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMApplied Digital's revenue soars, loss widens on growing AI investments - Reuters
Applied Digital's revenue soars, loss widens on growing AI investments Reuters
October 7, 2026 at 09:23 PMCanada's Weston family to buy UK's Boots in $8.9 billion deal - Reuters
Canada's Weston family to buy UK's Boots in $8.9 billion deal Reuters
October 7, 2026 at 04:53 PM